Assenagon Asset Management S.A. Has $67.55 Million Position in Merck & Co., Inc. (NYSE:MRK)

Assenagon Asset Management S.A. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 5.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 802,404 shares of the company’s stock after acquiring an additional 43,140 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Merck & Co., Inc. were worth $67,546,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Fox Run Management L.L.C. boosted its holdings in Merck & Co., Inc. by 4.4% in the third quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock valued at $238,000 after acquiring an additional 118 shares during the last quarter. First Command Bank boosted its holdings in Merck & Co., Inc. by 1.4% in the third quarter. First Command Bank now owns 8,599 shares of the company’s stock valued at $724,000 after acquiring an additional 118 shares during the last quarter. Allworth Financial LP boosted its holdings in Merck & Co., Inc. by 1.9% in the third quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock valued at $528,000 after acquiring an additional 119 shares during the last quarter. Stillwater Investment Management LLC boosted its holdings in Merck & Co., Inc. by 2.6% in the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock valued at $402,000 after acquiring an additional 120 shares during the last quarter. Finally, Southeast Asset Advisors Inc. boosted its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock valued at $449,000 after acquiring an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 74.99% of the company’s stock.

Several equities analysts recently issued reports on MRK shares. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a report on Tuesday, September 3rd. Bank of America started coverage on Merck & Co., Inc. in a report on Wednesday. They issued a “neutral” rating and a $90.00 price target on the stock. Credit Suisse Group reiterated a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Mizuho reiterated a “buy” rating and issued a $97.00 price target on shares of Merck & Co., Inc. in a report on Sunday, September 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $94.00.

NYSE:MRK opened at $84.45 on Thursday. Merck & Co., Inc. has a 1-year low of $66.10 and a 1-year high of $87.35. The business’s 50-day moving average price is $84.45 and its two-hundred day moving average price is $82.30. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $216.84 billion, a price-to-earnings ratio of 19.46, a PEG ratio of 1.72 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. Merck & Co., Inc.’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 earnings per share. Sell-side analysts predict that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date was Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

In other news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Cost of Goods Sold (COGS)

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.